AVROBIO

AVROBIO is a clinical-stage lentiviral gene therapy company, powered by plato®. Their vision is to bring personalized gene therapy to the world by targeting the root cause of genetic diseases. They achieve this by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal of durably expressing the therapeutic protein throughout the body, including the central nervous system. Their first-in-class pipeline includes clinical programs for Gaucher disease and Hunter syndrome, as well as a preclinical program for Pompe disease. Their proprietary plato® gene therapy platform is scalable for planned global commercialization. Founded in 2015 and headquartered in Cambridge, Mass. Their last investment was a $60.00M Series B investment on 01 February 2018, with participation from Atlas Venture, SV Health Investors, Aisling Capital, Brace Pharma Capital, Citadel, Cormorant Asset Management, Morningside Venture Partners, Clarus Ventures, Leerink Partners, and Eventide. For additional information, visit avrobio.com, and follow them on Twitter and LinkedIn.